Emanuele Giurisato Curriculum Vitae
Total Page:16
File Type:pdf, Size:1020Kb
Emanuele Giurisato Curriculum Vitae Present position: Lecturer at University of Siena. Department of Biotechnology, Chemistry and Pharmacy, University of Siena. Via Aldo Moro, 1 53100, Siena, Italy Phone: +39 0577 232125 (office) e-mail: [email protected] Visiting scientist at University of Manchester Faculty of Biology, Medicine and Health Oxford Road, M13 9PT, Manchester, UK e-mail: [email protected] Education and training: 2014-2016 Marie-Curie Fellowship (I-MOVE 2013-1-OUT-24-EXP) University of Manchester 2009-present Lecturer at University of Siena 2008 Post-doctoral fellowship Department of Physiopathology Molecular Medicine and Public Health, University of Siena, Italy 2003-2007 Post-doctoral fellowship Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO (USA) 1999-2002 Ph.D student in “Molecular Medicine” Department of Physiopathology Molecular Medicine and Public Health, University of Siena, Italy 1996-1999 Research assistant, Department of Biomedical Experimental Sciences, CRIBI (University of Padua, Italy) 1996 BSc, Biological Sciences (specialization in Molecular Biology), Department of Biomedical Experimental Sciences, (University of Padua, Italy) Research experience: Nov.’96 -Sept. ‘99: Research assistant at the University of Padua, Department of Biomedical Experimental Sciences, CRIBI. Advisor: Dr. M. Cantini Telethon projects A101 “Myoblast-selective mitogens released by macrophage as a tool for muscle regeneration and gene therapy” and A095 “FasL engineered myoblasts can escape from death: requisite for immune protection in gene therapy via myoblast”. Oct.1999-Dec 2002: Ph. D. student in “Molecular Medicine” at the University of Siena. Advisor: Prof. A. Benedetti Research project: (i) role of plasma-membrane microdomains (rafts) in cellular responses to stimulatory molecules in T lymphocytes, (ii) Calcium signalling in T cells and (iii) involvement of lipid rafts during the immunological synapse formation. Feb.2003-Sept 2007: Postdoc fellowship at the Department of Pathology and Immunology, Washington University School of Medicine, St. Louis (Missouri, USA). Advisor: Prof. A. S. Shaw Project research: (i) PI3-kinase activation and NK immunological synapse formation, (ii) molecular mechanisms involved in NKG2D-DAP10 induced killing of tumor cells (iv) role of MAPKs and scaffold molecule KSR on NK and CD8+ T cells effectors function. 1 Oct 2007-Oct 2008: Postdoc fellowship at the Department of Physiopathology Molecular Medicine and Public Sanity, University of Siena. Research project: (i) role of scaffold molecules KSR on CTL and NK cells functions (ii) MAPK activation and calcium signalling in lymphocytes (iii) activating receptor NKG2D and immunological synapse. May 2014-April 2016: Marie-Curie Fellowship (I-MOVE 2013-1-OUT-24-EXP) University of Manchester, UK. Research project : (i) role of MAPK signaling in Tumor-associated macrophages cells (ii) scaffold MAPK and cancerogenesis. Home Office Modular training and research experience: Home Office Modular Training Course for prospective personal licensees “Scientific Procedures on Living Animals” at the University of Manchester. Personal Licence n° I43AC3D64 (7/10/2014). Specific training: schedule 1 training and competence; Breeding and maintenance of genetically altered animals; Induction and maintenance of general anaesthesia; Subcutaneous or intraperitoneal implantation or removal of cells or tissue; Administration of substances topically to the skin; Administration of substances by intravenous injection. Transgenic mouse model research: carcinogenesis studies using the LysM-Cre mice (Cre recombinase system under the control of lysozyme 2 promoter) and inducible gene inactivation based on tamoxifen-inducible Cre-mediated recombination system driven by the keratin 14 promoter (K14-Cre/ER) or CMV promoter (CMV-Cre/ER). Research of interest 1: inflammation-driven cancer, macrophages and tumor microenvironment. 2: ERK5-MAPK signaling in cancer immunology. 3: scaffold KSRs and Ras-dependent cancerogenesis. Research grants 2008-Grant: Istituto Toscano Tumori (Institute Toscany Tumours, ITT Research Grant 2008) “Role of scaffold molecule KSR1 on immunosurveillance and anticancer drug sensitivity in human cancer”. Principle Investigator. Duration: 24 months. 2009-Grant: Italian Ministry for University and Research (PRIN 2009, CKARAL) “Role of KSR1 protein In tumorigenesis and resistance to anti-EGFR therapies”. Principle Investigator. Duration: 36 months. 2014-Grant: EC- Marie Curie i-MOVE, University of Manchester. Principle Investigator. Duration: 24 months. 2019-2021 North West cancer Research project grant “The role of the ERK5 signalling axis in BRAF inhibitor-resistant melanoma progression“.Co-applicant. Duration: 36 months. 2019-2024 AIRC project grant “Modeling mucosal melanomas. Understanding the immune contexture and the molecular landscape for therapeutic targeting”. Collaborator. Duration: 60 months. Membership European Association Cancer Research (EACR), Italian Society of Immunology, Clinic and Allergology (SIICA). Didactical Activity 2 Degree course of Medical Biotechnology, University of Siena. Integrated course of Experimental Medicine (Module of Immunology and Pathology). AA 2009-2010, AA 2010-2011, AA 2011-2012, AA 2012-2013, 2013-2014, AA 2016-2017, AA 2017-2018, AA 2019-2020. Degree course of Medicine, University of Siena. Integrated course of Microbiology and Immunology (Module of Immunology). AA 2009-2010, AA 2010-2011, AA 2011-2012, AA 2012- 2013, AA 2013-2014, AA 2016-2017, AA 2017-2018. School of Specialization “Farmacia Ospedaliera”, University of Siena, course of Pain therapy: pathological aspects. AA 2018-2019, AA 2019-2020. List of Publications Consoli, Barbieri G, Picciolini M, Medicina D, Bugatti M, Tovazzi V, Liserre B, Zambelli C, Zorzi F, Berruti A, Giurisato E and Vermi W (2020). Clinical and molecular characterization of a rare complex BRAF mutation involving codon V600 and K601 in primary cutaneous melanoma. Frontiers of Oncology (under revision) Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebri B, Zhang J, Russo I, Wang J, Santucci A, Finegan K, Gray N, Vermi W, and Tournier C (2020). The extracellular- regulated protein kinase 5 is required for mediating macrophage proliferation associated with the development of malignant tumors. Cancer Research (under revision). Pearson AJ, Fullwood P, Tapia GT, Prise I, Smith M, Xu Q, Jordan A, Giurisato E, Whitmarsh AJ, Francavilla C and Tournier C (2020). Discovery of a gatekeeper residue in the C terminal tail of the extracellular signal-regulated protein kinase 5 (ERK5). International Journal of Molecular Sciences 21(3), 929. doi.org/10.3390/ijms21030929. Benerini Gatta L, Melocchi L, Bugatti M, Missale F, Lonardi S, Cristinelli L, Belotti S, Simeone C, Ronca R, Licini S, Tardanico R, Zanetti B, Chan SR, Giurisato E, Calza S, and Vermi W (2019). hyper-activation of STAT3 sustains progression of non-papillary basal-type bladder cancer via FOSL1 regulome. Cancers 11(9) pii: E1219. doi.10.3390/cancers11091219 Moretti E, Collodel G, Belmonte G, Noto D and Giurisato E. (2019) Defective spermatogenesis and testosterone levels in KSR1 deficient mice. Reproduction, Fertility and Development. 2019 Apr 15. doi: 10.1071/RD18386. Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, Vermi W, Xia Z and Tournier C. (2018). Myeloid ERK5 deficiency suppresses tumor growth by blocking pro-tumor macrophage polarization via STAT3 inhibition. Proc Natl Acad Sci U S A. Mar 20;115(12):E2801-E2810. doi: 10.1073/pnas.1707929115. PMID:29507229. Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, Sarhan AR, Hillen A, Velde GV, Gray NS, Alessi DR, Cunningham DL, Tournier C, Johnston SA, May RC (2017). Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. Science Advances 3(8):e1700898.doi:10.1126/sciadv.1700898. PMID: 28835924. Young H, Rowling E, Bugatti M, Giurisato E, Luheshi H, Arozarena I, Acosta JC, Kamarashev J, Frederick D, Cooper Z, Reuben A, Gil J, Flaherty K, Wargo J, Vermi W, Smith M, Wellbrock C, and Hurlstone A. (2017). An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. 3 J Exp Medicine 214(6):1691-1710. doi: 10.1084/jem.20160855. PMID: 28450382 Giurisato E, Tournier C. (2016). Can tumour cells proliferate without ERK5? Cell Cycle. Mar 3;15(5):619-20. doi: 10.1080/15384101.2016.1143272. PMID: 26822978 Gambini L, Rizzi L, Pedretti A, Taglialatela-Scafati O, Carucci M, Pancotti A, Galli C, Read M, Giurisato E, Romeo S, Russo I. (2015). Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region. PLoS One. Nov 13;10(11):e0142509. doi: 10.1371/journal.pone.0142509. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0146627. PMID: 26566224. Bottiglione F, Giurisato E. (2015) Scaffold KSR2 overexpression is associated with melanoma A375 cells resistance to Vemurafenib. Med Res Arc. Nov 12; 2(7), doi: 10.18103/mra.v2i7.384. ISSN 2375-1924. Moretti E, Collodel G, Mazzi L, Russo I, Giurisato E. (2015). Ultrastructural study of spermatogenesis in KSR2 deficient mice. Transgenic Res. 24(4):741-51. Giurisato E, Gamberucci A, Ulivieri C, Marruganti S, Rossi E, Giacomello E, Randazzo D, Sorrentino V. (2014). The KSR2-calcineurin complex regulates STIM1-ORAI1 dynamics and store-operated calcium entry (SOCE). Mol Biol